HomeCompareFREQ vs CL

FREQ vs CL: Dividend Comparison 2026

FREQ yields 667.56% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FREQ wins by $614802.01M in total portfolio value
10 years
FREQ
FREQ
● Live price
667.56%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$614802.06M
Annual income
$474,868,230,549.69
Full FREQ calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — FREQ vs CL

📍 FREQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFREQCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FREQ + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FREQ pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FREQ
Annual income on $10K today (after 15% tax)
$56,742.32/yr
After 10yr DRIP, annual income (after tax)
$403,637,995,967.24/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, FREQ beats the other by $403,637,991,375.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FREQ + CL for your $10,000?

FREQ: 50%CL: 50%
100% CL50/50100% FREQ
Portfolio after 10yr
$307401.05M
Annual income
$237,434,117,975.83/yr
Blended yield
77.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

FREQ
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$1.40
+367.3% upside vs current
Range: $1.40 — $1.40
Altman Z
-7.4
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FREQ buys
0
CL buys
0
No recent congressional trades found for FREQ or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFREQCL
Forward yield667.56%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$614802.06M$40.8K
Annual income after 10y$474,868,230,549.69$5,401.96
Total dividends collected$603369.48M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold
Analyst price target$1.40$92.45

Year-by-year: FREQ vs CL ($10,000, DRIP)

YearFREQ PortfolioFREQ Income/yrCL PortfolioCL Income/yrGap
1← crossover$77,456$66,755.67$11,012$312.01+$66.4KFREQ
2$566,112$483,234.18$12,196$412.95+$553.9KFREQ
3$3,906,567$3,300,827.31$13,599$549.66+$3.89MFREQ
4$25,467,892$21,287,865.51$15,288$736.64+$25.45MFREQ
5$156,952,466$129,701,821.96$17,353$995.28+$156.94MFREQ
6$914,968,107$747,028,968.25$19,926$1,357.80+$914.95MFREQ
7$5,048,988,394$4,069,972,519.36$23,194$1,873.82+$5048.97MFREQ
8$26,392,111,970$20,989,694,387.90$27,439$2,621.52+$26392.08MFREQ
9$130,779,275,796$102,539,715,988.68$33,088$3,727.38+$130779.24MFREQ
10$614,802,055,652$474,868,230,549.69$40,806$5,401.96+$614802.01MFREQ

FREQ vs CL: Complete Analysis 2026

FREQStock

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Full FREQ Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this FREQ vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FREQ vs SCHDFREQ vs JEPIFREQ vs OFREQ vs KOFREQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.